acacia
nilotica
tropic
subtrop
medicin
plant
belong
fabacea
famili
doubt
medicin
plant
play
vital
role
drug
discoveri
sinc
affluent
bioactiv
phytochem
constitu
valuabl
treatment
variou
diseas
particularli
caus
recent
threat
attack
public
health
includ
cancer
multidrugresist
bacteri
infect
diabet
mellitu
chronic
inflammatori
system
diseas
higher
incid
cancer
mortal
rate
emerg
bacteri
resist
declin
antibacteri
research
sever
pharmaceut
compani
huge
preval
complic
associ
diabet
mellitu
well
longterm
suffer
associ
chronic
inflammatori
system
diseas
rheumatoid
arthriti
multipl
sclerosi
lead
forc
encourag
us
particip
fight
probabl
threat
issu
attain
via
discoveri
develop
effici
innov
anticanc
antibacteri
antidiabet
antiinflammatori
drug
unfortun
drug
discoveri
timeconsum
costiv
well
difficult
process
henc
necessit
involv
sophist
techniqu
drug
discoveri
process
order
overcom
limit
recent
one
promis
sophist
techniqu
comput
tool
computeraid
drug
design
valuabl
impact
discoveri
develop
newer
drug
reduct
time
cost
includ
ligandbas
virtual
screen
base
search
compound
highest
probabl
pharmacolog
activ
molecular
dock
reli
energybas
score
function
identifi
ligandtarget
complex
lowest
energi
moreov
involv
softwar
pharmacokinet
toxic
druglik
predict
work
mani
algorithm
includ
graphbas
signatur
mani
studi
concern
applic
comput
tool
discoveri
naturalderiv
drug
conduct
nilotica
opul
mani
phytochem
constitu
includ
tannin
alkaloid
terpenoid
flavonoid
mani
studi
conduct
result
evidencebas
pharmacolog
data
reveal
potenti
pharmacolog
activ
phytochem
compound
includ
anticanc
antibacteri
antidiabet
antiinflammatori
activ
make
plant
promis
sourc
develop
innov
safe
biodegrad
drug
great
activ
chemic
structur
activ
nilotica
phytochem
constitu
elucid
correl
respons
phytochem
constitu
treatment
diseas
conduct
determin
exact
target
phytochem
constitu
bind
mechan
action
perform
consequ
base
establish
literatur
studi
aim
identifi
exact
target
phytochem
constitu
bind
exert
pharmacolog
activ
util
comput
method
tool
studi
understand
mechan
action
within
current
drug
design
pipelin
drug
target
identif
import
step
understand
probabl
mechan
action
increas
confid
reduc
attrit
clinic
trial
furthermor
aim
predict
pharmacokinet
adm
properti
safeti
profil
intent
identifi
best
drug
candid
qsarbas
virtual
screen
character
great
fast
throughput
respect
hit
rank
molecular
dock
valuabl
predict
stabil
ligandtarget
complex
reflect
biolog
activ
pharmacokinet
toxic
druglik
predict
help
identifi
best
drug
candid
knowledg
studi
conduct
chemic
structur
report
nilotica
phytochem
constitu
compound
drawn
via
marven
sketch
softwar
version
fig
structur
gener
format
open
babel
softwar
minim
optim
cresset
flare
softwar
accur
type
calcul
method
screen
exact
target
phytochem
constitu
bind
perform
via
similar
ensembl
search
tool
targetnet
web
server
compound
structur
submit
smile
format
target
higher
probabl
score
select
valid
via
molecular
dock
studi
target
linkag
predict
target
diseas
attain
via
uniprot
pharo
therapeut
target
databas
result
list
tabl
structur
select
target
virtual
screen
obtain
rcsb
protein
data
bank
structur
better
resolut
valid
score
select
studi
order
valid
dock
result
multipl
xray
crystallograph
structur
target
download
pdb
format
structur
practic
determin
structur
swissmodel
web
server
raptorx
web
server
use
structur
model
download
pdb
format
target
prepar
carri
cresset
flare
softwar
accord
default
set
prepar
target
structur
minim
via
cresset
flare
softwar
normal
type
calcul
method
target
input
softwar
pdb
format
prepar
report
nilotica
phytochem
constitu
molecular
dock
studi
carri
describ
dock
calcul
carri
cresset
flare
softwar
normal
mode
default
set
grid
box
defin
accord
cocrystal
ligand
absenc
cocrystal
ligand
grid
box
defin
via
pick
activ
site
amino
acid
besid
nilotica
phytochem
constitu
drug
well
known
bind
predict
target
select
randomli
therapeut
target
pharo
databas
cocrystal
ligand
use
posit
control
compound
target
input
pdb
format
respect
result
list
tabl
fig
intestin
absorpt
volum
distribut
bloodbrain
barrier
pglycoprotein
cytochromep
enzym
inhibit
renal
substrat
probabl
total
clearanc
predict
via
pkcsm
swissadm
web
server
moreov
hepatotox
skin
sensit
herg
potassium
channel
inhibit
ame
toxic
human
maximum
toler
dose
carcinogen
oral
rate
acut
chronic
toxic
predict
via
pkcsm
web
server
default
set
via
submit
chemic
structur
smile
format
result
pharmacokinet
list
tabl
toxic
tabl
probabl
nilotica
phytochem
constitu
drug
candid
carri
via
appli
lipinski
ghose
veber
egan
muegg
filter
addit
lead
like
synthet
access
use
predict
medicin
chemistri
friendli
predict
carri
via
swissadm
web
server
via
submit
chemic
structur
smile
format
result
list
tabl
consist
reproduc
use
tool
includ
molecular
dock
valid
resubmiss
compound
mani
time
anticanc
activ
nilotica
attribut
suppress
oncogen
transform
progress
develop
dna
replic
transcript
moreov
prevent
cancer
cell
prolifer
invas
angiogenesi
well
suppress
drug
resist
induct
apoptosi
antibreast
cancer
activ
due
inhibit
aromatas
enzym
estrogen
receptor
beta
contrast
antiprost
cancer
activ
due
control
metastat
behavior
prostat
cancer
via
interact
nuclear
receptor
roralpha
inhibit
steroid
alphahydroxylas
tabl
fig
antibacteri
activ
nilotica
attribut
prevent
fatti
acid
peptidoglycan
biosynthesi
well
prevent
bacteri
resist
betalactam
antibiot
fatti
acid
biosynthesi
inhibitori
activ
differ
type
bacteria
includ
mycobacterium
pseudomona
aeruginosa
vibrio
cholera
antivir
activ
attribut
action
tolllik
receptor
antihiv
activ
due
inhibit
hiv
integras
enzym
anticoronaviru
activ
due
coronaviru
replicas
polyprotein
ab
enzym
antiplasmodi
activ
attribut
inhibit
enzym
protein
kinas
pfmrk
aspartyl
aminopeptidas
well
prevent
fatti
acid
biosynthesi
via
inhibit
enzym
acylacp
dehydratas
fabz
hydroxyacyl
acylcarrierprotein
dehydratas
tabl
antidiabet
activ
attribut
interact
insulin
receptor
glycogen
phosphorylas
enzym
sodiumglucos
cotransport
well
aldos
reductas
enzym
tabl
antiinflammatori
activ
attribut
inhibit
enzym
arachidon
phospholipas
receptorinteract
serinethreonin
protein
kinas
xanthin
dehydrogenaseoxidas
well
interact
macrophag
migrat
inhibitori
factor
tabl
antidiarrh
activ
attribut
interact
opioid
receptor
mutyp
deltatyp
antiplatelet
activ
attribut
interact
receptor
inhibit
enzym
acetylcholinesteras
contribut
anticholinesteras
activ
accord
result
acacetin
kaempferol
flavon
lupenon
lupeol
niloctan
quercetin
highest
gastrointestin
absorpt
tissu
distribut
vd
respect
total
clearanc
moreov
flavon
nilobam
niloctan
permeabl
bloodbrain
barrier
bbb
besid
flavon
lupenon
lupeol
found
subject
metabol
via
enzym
tabl
moreov
mollisacacidin
catechin
epicatechin
nilotican
leucocyanidin
nilobam
free
drugdrug
interact
via
inhibit
cytochromep
cyp
pglycoprotein
pgp
ii
enzym
tabl
accord
result
ellag
acid
kaempferol
quercetin
nontox
well
noncarcinogen
tabl
accord
result
mollisacacidin
acacetin
catechin
epicatechin
kaempferol
naringenin
niloctan
quercetin
found
best
lead
drug
candid
good
synthet
access
follow
digal
acid
ellag
acid
leucocyanidin
melacacidin
tabl
despit
enorm
conduct
studi
pharmacolog
activ
nilotica
determin
target
contribut
activ
understand
mechan
action
well
assess
pharmacokinet
safeti
druglik
probabl
import
issu
conduct
yet
studi
requir
bring
plant
drug
discoveri
pipelin
design
novel
drug
broadspectrum
therapeut
activ
safeti
identifi
target
targetnet
web
server
util
qsar
model
base
chemogenom
data
predict
algorithm
similar
ensembl
search
tool
use
valid
predict
target
web
server
molecular
dock
studi
perform
use
cresset
flare
softwar
use
lead
finder
program
dock
calcul
moreov
pkcsm
swissadm
web
server
use
predict
pharmacokinet
adm
absorpt
distribut
metabol
elimin
toxic
druglik
probabl
total
predict
target
form
virtual
screen
highest
probabl
valid
molecular
dock
target
interact
acacetin
cell
divis
control
protein
homolog
prevent
oncogen
transform
inhibit
lymphoma
kinas
quercetin
cyclindepend
kinas
ellag
acid
acacetin
aurora
b
ellag
acid
quercetin
serinethreonin
protein
kinas
quercetin
protooncogen
tyrosineprotein
kinas
src
ellag
acid
tankyras
acacetin
well
phase
induc
phosphatas
digal
acid
epicatechin
prevent
cancer
progress
develop
moreov
inhibit
divis
protein
kinas
ellag
acid
serinethreonineprotein
kinas
quercetin
ellag
acid
kaempferol
well
dna
topoisomeras
suppress
dna
replic
inhibit
kinas
acacetin
telomeras
revers
transcriptas
leucocyanidin
quercetin
ellag
acid
suppress
transcript
inhibit
tyrosineprotein
kinas
lyn
enzym
ellag
acid
prevent
cancer
cell
prolifer
well
inhibit
receptor
protooncogen
tyrosineprotein
kinas
src
ellag
acid
protein
kinas
c
epsilon
kaempferol
naringnen
suppress
cancer
cell
invas
furthermor
inhibit
ephrin
type
b
receptor
plateletderiv
growth
factor
receptor
ellag
acid
vascular
endotheli
growth
factor
receptor
quercetin
well
focal
adhes
kinas
enzym
ellag
acid
quercetin
suppress
angiogenesi
inhibit
pglycoprotein
transport
kaempferol
quercetin
well
atp
bind
cassett
subfamili
g
member
leucocyanidin
quercetin
ellag
acid
kaempferol
suppress
cancer
cell
resist
interact
lupeol
quercetin
ellag
acid
kaempferol
enzym
induc
nitric
oxid
synthas
macrophag
promot
tumoricid
action
inhibit
protein
leucocyanidin
quercetin
ellag
acid
kaempferol
induc
myeloid
leukemia
differenti
protein
acacetin
quercetin
ellag
acid
kaempferol
well
interact
enzym
caspas
quercetin
ellag
acid
kaempferol
deathassoci
protein
kinas
kaempferol
induc
cancer
cell
apoptosi
consequ
compound
show
substanti
anticanc
activ
tabl
interact
kaempferol
quercetin
enzym
acyl
carrier
protein
reductas
fabg
interact
quercetin
enoylacyl
carrier
protein
reductas
inhibit
bacteri
fatti
acid
biosynthesi
essenti
format
bacteri
membran
phospholipid
lead
impair
cellular
envelop
structur
function
abil
form
biofilm
well
increas
suscept
environment
stress
moreov
inhibit
enzym
dalanin
dalanin
ligas
quercetin
suppress
peptidoglycan
biosynthesi
vital
bacteri
cell
structur
caus
loss
bacteri
cell
integr
therefor
compound
signific
antibacteri
activ
tabl
interact
leucocyanidin
ellag
acid
kaempferol
quercetin
tolllik
receptor
activ
innat
immun
receptor
help
recognit
microbi
dna
interact
digal
acid
acacetin
ellag
acid
kaempferol
quercetin
hiv
integras
enzym
inhibit
viral
dna
integr
host
dna
lead
suppress
replic
cycl
interact
quercetin
coronaviru
replicas
polyprotein
ab
inhibit
transcript
replic
viral
rna
thu
nilotica
phytochem
constitu
exhibit
consider
antivir
activ
tabl
interact
acacetin
enzym
protein
kinas
pfmrk
disrupt
regul
plasmodi
cell
cycl
interact
quercetin
mollisacacidin
enzym
aspartyl
aminopeptidas
prevent
invas
host
erythrocyt
degrad
host
hemoglobin
furthermor
interact
quercetin
plasmodi
enzym
acylacp
dehydratas
fabz
hydroxyacyl
acylcarrierprotein
dehydratas
inhibit
fatti
acid
biosynthesi
import
plasmodi
membran
subsequ
nilotica
phytochem
constitu
show
consider
antiplasmodi
activ
tabl
interact
ellag
acid
insulin
receptor
promot
glucos
uptak
lower
blood
glucos
level
interact
quercetin
enzym
glycogen
phosphorylas
inhibit
glycogenolysi
reduc
hyperglycemia
moreov
interact
sodiumglucos
cotransport
inhibit
renal
glucos
reabsorpt
lead
reduct
plasma
glucos
level
interact
dicatechin
leucocyanidin
ellag
acid
kaempferol
quercetin
aldos
reductas
enzym
suppress
develop
secondari
diabet
complic
well
interact
ellag
acid
quercetin
betasecretas
enzym
upregul
insulin
receptor
liver
success
nilotica
phytochem
constitu
signific
antidiabet
activ
tabl
interact
ellag
acid
kaempferol
quercetin
enzym
arachidon
interact
digal
acid
acacetin
ellag
acid
kaempferol
quercetin
receptorinteract
serinethreonin
protein
kinas
interrupt
inflammatori
respons
interact
mollisacacidin
naringnen
ellag
acid
kaempferol
quercetin
enzym
prevent
format
inflammatori
mediat
prostaglandin
interact
digal
acid
kaempferol
quercetin
phospholipas
enzym
prevent
initi
inflammatori
respons
moreov
interact
digal
acid
acacetin
ellag
acid
kaempferol
quercetin
xanthin
dehydrogenaseoxidas
enzym
inhibit
format
uric
acid
reactiv
oxygen
speci
thu
nilotica
phytochem
constitu
exhibit
consider
antiinflammatori
activ
tabl
interact
dicatechin
mu
delta
opioid
receptor
lead
antisecretori
antitransit
action
inhibit
diarrhea
interact
receptor
inhibit
platelet
activ
consequ
consider
antidiarrh
antiplatelet
activ
respect
tabl
chemogenomicbas
qsar
model
targetnet
web
server
strictli
evalu
valid
lead
respect
screen
result
furthermor
lead
finder
program
cresset
flare
softwar
character
combin
genet
algorithm
differ
optim
strategi
lead
great
effici
robust
accuraci
speed
calcul
musab
ibrahim
et
al
found
result
molecular
dock
studi
novel
synthes
cox
enzym
inhibitor
conduct
cresset
flare
softwar
align
result
conduct
vivo
studi
depend
obtain
result
predict
target
could
consider
accuraci
sinc
pharmacolog
activ
depend
pharmacodynam
properti
also
pharmacokinet
properti
moreov
drug
safeti
assess
druglik
probabl
synthet
access
import
issu
identif
best
nilotica
phytochem
constitu
attain
assess
issu
collect
pharmacokinet
concern
studi
entranc
movement
chang
leav
drug
bodi
higher
absorpt
gastrointestin
tract
lead
higher
drug
concentr
blood
higher
volum
distribut
provid
higher
suppli
bodi
tissu
adequ
metabol
elimin
prevent
accumul
drug
bodi
henc
reduc
toxic
consequ
consider
pharmacokinet
drug
design
essenti
task
instanc
lupenon
highli
lipophil
henc
higher
absorpt
percent
contrast
hydrophil
group
ellag
acid
reduc
absorpt
percent
howev
still
high
absorpt
percent
higher
absorpt
make
lupenon
highli
bioavail
niloctan
permeabl
bbb
therefor
concentr
reach
brain
target
ellag
acid
permeabl
bbb
predict
volum
distribut
vd
melacacidin
lkg
highest
one
mean
highest
distribut
bodi
tissu
contrari
nilobam
highest
predict
total
clearanc
mean
fastest
one
elimin
bodi
tabl
moreov
inhibit
cytochromep
enzym
ellag
acid
decreas
biotransform
drug
metabol
lead
increas
concentr
may
increas
side
effect
consequ
drugdrug
interact
must
consider
bind
dicatechin
pglycoprotein
may
decreas
transport
drug
transport
transport
may
involv
drug
resist
pump
mechan
tabl
furthermor
predict
ame
toxic
epicatechin
lead
genotox
mutagen
predict
herg
ii
potassium
channel
inhibitori
effect
acacetin
prolong
qt
interv
ecg
increas
risk
potenti
fatal
ventricular
arrhythmia
subsequ
drug
consid
druglik
candid
tabl
besid
quercetin
violat
lipinski
rule
five
henc
good
candid
oral
activ
drug
well
violat
ghose
veber
egan
filter
therefor
good
leadlik
candid
tabl
accord
result
pharmacodynam
pharmacokinet
safeti
druglik
predict
collect
ellag
acid
kaempferol
quercetin
best
nilotica
phytochem
constitu
contribut
therapeut
activ
interact
predict
target
demonstr
mark
ligand
superimpos
control
compound
eg
fig
b
howev
may
activ
site
without
ligand
superimpos
eg
fig
ellag
acid
interact
aurora
kinas
enzym
two
bind
mode
fig
ellag
acid
kaempferol
quercetin
interact
steroid
alphahydroxylas
enzym
bind
mode
differ
bind
mode
control
galeteron
fig
follow
mollisacacidin
epicatechin
melacacidin
predict
ame
toxic
decreas
rank
predict
herg
ii
potassium
channel
inhibitori
effect
acacetin
decreas
rank
howev
good
pharmacodynam
pharmacokinet
profil
despit
effici
pharmacodynam
respect
safeti
profil
ellag
acid
kaempferol
quercetin
practic
compound
suffer
low
bioavail
albeit
predict
intestin
absorpt
high
tabl
reduc
bioavail
ellag
acid
attribut
poor
absorpt
rapid
elimin
bodi
predict
total
clearanc
ellag
acid
high
higher
topolog
polar
surfac
area
tpsa
tabl
contribut
poor
absorpt
reduc
absorpt
kaempferol
attribut
larger
particl
size
poor
water
solubl
reduc
bioavail
quercetin
attribut
poor
solubl
crystallin
form
bodi
temperatur
moreov
ellag
acid
kaempferol
quercetin
mani
polar
phenol
hydroxyl
group
structur
l
x
consequ
subject
direct
glucuronid
conjug
phase
ii
metabol
kaempferol
quercetin
rapidli
excret
urin
glucuronid
mainli
reduc
bioavail
affect
pharmacolog
activ
henc
maintain
pharmacolog
activ
bioavail
must
enhanc
nanosuspens
form
kaempferol
increas
absorpt
bioavail
administr
isoquercetin
increas
absorpt
bioavail
quercetin
bioavail
ellag
acid
kaempferol
quercetin
increas
bypass
enterohepat
phase
ii
conjug
eg
format
ester
deriv
use
novel
drug
deliveri
system
liposom
furthermor
coadministr
ginkgo
biloba
extract
kaempferol
quercetin
increas
bioavail
consequ
combin
ellag
acid
kaempferol
quercetin
optimum
treatment
choic
maxim
therapeut
activ
safeti
profil
well
overwhelm
limit
bioavail
natur
avail
one
plant
combin
therapeut
dose
addit
induc
drugdrug
interact
design
multitarget
drug
effect
promis
approach
treatment
complex
diseas
comput
method
includ
virtual
screen
substitut
vitro
vivo
method
howev
reduc
time
cost
difficult
drug
target
identif
therefor
studi
attempt
identifi
best
nilotica
phytochem
constitu
contribut
pharmacolog
activ
well
target
mean
studi
alon
suffici
judg
result
howev
experiment
studi
requir
valid
result
accord
result
pharmacodynam
pharmacokinet
safeti
druglik
predict
collect
ellag
acid
kaempferol
quercetin
best
nilotica
phytochem
constitu
contribut
therapeut
activ
consequ
recommend
use
ellag
acid
kaempferol
quercetin
combin
drug
via
novel
drug
deliveri
system
treatment
recent
diseas
attack
public
health
includ
cancer
multidrugresist
bacteri
infect
diabet
mellitu
chronic
inflammatori
system
diseas
moreov
recommend
wet
lab
studi
valid
result
